| [1] |
O'Doherty MJ. PET in oncology I——lung, breast, soft tissue sarcoma[J]. Nucl Med Commun, 2000, 21:224~229.
|
| [2] |
Brock CS, Meickle SR, Price P. Dose fluorine-18 fluorodeoxyglucose metabolic imaging of tumor benefit oncology[J]. Eur J Nucl Med, 1997, 24; 691~750.
|
| [3] |
Tamaki N,Tadamura E,Kudoh T,et al.Recent advances in nuclear cardiology in the study of coronary artery disease[J]. Ann Nucl Med,1997, 11:55~66.
|
| [4] |
Beanlands R,deKemp R,Smith S,et al.F-18-FDG PET imaging alters clinical decision making in patients with impaired ventricular function[J]. Am J Cardio,1997, 79:1092~1095.
|
| [5] |
Maes A,Mortelmans L,Nuyts J,et al.Importance of flow/metabolism studies in predicting late recovery of function following reperfusion in patients with acute mycardial infarction[J]. Eur Heart J,1997, 18:954~962.
|
| [6] |
Saha GB, MacIntyr WJ, Brunken RC, et al. Present Assessment of Myocardial Viability by Nuclear Imaging[J]. Semin Nucl Med, 1996, 26:315~335.
|
| [7] |
Bax J, Veening M, Visser F, et al. Optimal metabolic conditions during fluorine-18 fluorodeoxyglucose imaging:a comparative study using different protocols[J]. Eur J Nucl Med, 1997, 24:35~41.
|
| [8] |
Cremerius U, Bares R, Weis J, et al. Fasting improves discrimination of grading l and atypical or malignant meningioma in FDG-PET[J]. J Nucl Med, 1997, 38:26~30.
|